Ryan C, et al. - In this trial, the authors aimed to evaluate the informative data from non-dermatologic indications and to analyze the safety of adalimumab given every other week (EOW) and every week (EW) in individuals having hidradenitis suppurativa (HS) and psoriasis. They concluded that the safety of adalimumab EW and EOW was similar and consistent with the expected adalimumab adverse events (AEs) profile in patients with HS or psoriasis. In patients with dermatologic conditions, the safety of adalimumab EW dosing was supported by data comparing adalimumab EW and EOW dosing for Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.